 |
|
Two Miller School Faculty Members Inducted into Association of American Physicians
 |
| Margaret Fischl, M.D., professor of medicine, director of the AIDS Clinical Research Unit, and co-director of the Developmental Center for
AIDS Research, and Joshua Hare, M.D., the Louis Lemberg Professor of Medicine and director of the Interdisciplinary Stem Cell Institute. |
Two Miller School physicians are among the newest members of the prestigious Association of American Physicians (AAP), which was founded in 1885 for “the advancement of scientific and practical medicine.” Induction is considered a great honor, as members have included Nobel laureates and members of the National Academy of Sciences and the Institute of Medicine.
The UM honorees are Margaret Fischl, M.D., professor of medicine, director of the AIDS Clinical Research Unit, and co-director of the Developmental Center for AIDS Research, and Joshua Hare, M.D., the Louis Lemberg Professor of Medicine and director of the Interdisciplinary Stem Cell Institute.
“We are so proud to have two of our faculty members inducted into the AAP as a testament to their great scientific, clinical, and other academic accomplishments,” said Dean Pascal J. Goldschmidt, M.D. “Drs. Fischl and Hare are stellar physician-scientists who have made seminal contributions to advancing science in their chosen fields. Both of them are exceptional pioneers.”
Fischl has been at the forefront of anti-retroviral research and has led numerous studies dealing with HIV/AIDS and Kaposi’s sarcoma, including the first studies evaluating zidovudine (AZT). She also served as senior author of a study published in The New England Journal of Medicine that proved the effectiveness of triple-combination drug therapy using the newest class of anti-retroviral drugs called protease inhibitors. Additionally, Fischl was the first physician to demonstrate that use of trimethoprim-sulfamethoxozole in the prevention of HIV-related pneumocystis carinii pneumonia improved survival rates. Her research continues to focus on novel treatment approaches, including the assessment of a new retrovirus-based vaccine.
Hare, who founded the Miller School’s Interdisciplinary Stem Cell Institute in 2008, has made major contributions to mechanistic, translational, and clinical research in the field of heart failure and
left ventricular dysfunction. He is considered one of the leading clinician-scientists advancing stem cell therapy for heart disease. Hare is best known for his pioneering work in translating stem cell research to early observations in human populations, showing that bone marrow mesenchymal stem cells can heal injured hearts in clinically meaningful ways. |
|
|
